Funding Received
$112.5 Million in 3 Rounds from 1 Investor
Most Recent Funding
$105 Million Series D on April 15, 2014
Headquarters:
Seattle, WA
Description:
Adaptive Biotechnologies offers research and diagnostic tools for scientists and clinicians involved in genomic immunology.
Founders:
Chad Robins, Christopher Carlson, Harlan Robins
Categories:
Health Care, Bio-Pharm, Biotechnology
Website:
http://adaptivebiotech.com

Company Details

Update

Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

Current Team (10)

Update

Funding Rounds (3) - $105M

Update

Board Members and Advisors (15)

Update

Offices/Locations (1)

Update
  • Office

    1551 Eastlake Ave E

    Suite 200

    Seattle, WA 98102

    USA

Images (3)

Update
  • Uwymliljb7xyjrnzqvpe
  • Putiuzvnruha0jehzc1g
  • 4c4351b273d4b3f505021923b7bc1440